This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ABO-201

Abeona Therapeutics, Inc.

Drug Names(s): Recombinant AAV9 expressing CLN3, AAV CLN3

Description: ABO-201 is an adeno-associated virus (AAV) gene therapy program expressing ceroid-lipofuscinosis, neuronal 3 (CLN3) for the treatment of the juvenile form of NCL, called Batten disease (some also use Batten disease to refer to all forms of NCL). Mutation in the CLN3 is a major cause of the juvenile form, but its function is not entirely clear.


ABO-201 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug